Biotech news for Thursday, May 28, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Immunic ( IMUX ) Wednesday named Erik Lundgren as CEO, effective May 22, 2026, with employment beginning on June 1, 2026. Lundgren succeeds Daniel Vitt , Ph.D., who will retain responsibility for scientific strategy and portfolio advancement while remaining a…
An advisory panel of the U.S. Food and Drug Administration will meet this week to discuss and vote on the composition of the 2026–2027 formula for COVID shots to be used during the next immunization drive against the virus. At
Silexion Therapeutics ( SLXN ) on Tuesday announced a 1-for-10 reverse share split of its ordinary shares, effective on market close of May 28, 2026. The par value of the ordinary shares will be proportionately increased from $0.0135 per share to $0.135 per sh…
iQoncept/iStock via Getty Images As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factors such as valuation, growth…
Torsten Asmus As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factors such as valuation, growth, profitability, mo…
iQoncept/iStock via Getty Images As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factors such as valuation, growth…
alexsl Shares of BridgeBio Pharma ( BBIO ) slipped in the premarket on Tuesday after Raymond James downgraded the stock, citing the impact from the loss of exclusivity for Pfizer’s ( PFE ) heart drug Vyndamax, which rivals the company’s lead asset, Attruby. Ra…
koto_feja Corbus Pharma ( CRBP ) lost ~10% in the premarket on Tuesday after the Norwood, Massachusetts-based biotech announced the latest data from a Phase 1/2 trial for CRB-701 (SYS6002), its lead asset targeting solid tumors. Citing an April 1, 2026, data c…